摘要
目的:探讨初治卵巢癌组织多药耐药基因(MDR_1)表达水平及其对相关药物抗肿瘤作用的影响.方法:用逆转录酶链聚合反应(RT—PCR)法对37例初治卵巢癌组织MDR_1表达水平进行了定量测定.结果:37例卵巢癌组织均有MDR_1表达,其中浆液性癌的表达水平为0.75±0.22,粘液性癌为1.03±0.28,内膜样癌为0.57±0.11,3种病理类型之间MDR_1的表达水平有显著性差异(P<0.05);34例卵巢癌的小鼠肾包膜下移植肿瘤药敏测定(SRCA)肿瘤药敏试验成功,此34例的MDR_1表达水平与ADM及VCR在SRCA中的抗肿瘤作用呈负相关,与VP16的抗肿瘤作用无相关关系.结论:初治卵巢癌存在固有的MDR_1表达,MDR_1的表达降低相关药物的抗肿瘤作用.
Objective:To investigate the expresson level of MDR_(1) in Ovarian Carcinoma and its effection on the antitumor ac-tivity of MDR_(1) reltated drugs. Methods: The MDR_(1) gene expression in fresh ovarian carcinom spemens from 37 patients were analyzed by reverse transcription polymerase chain reaction, and the antitumor activity of three MDR_(1) related drug (ADM. VCR. VP16) was mesaurde by subrenal capsule assay. Results; The MDR_(1) expression was demonstrated in all 37 case of ovarian carcinomas; The MDR_(1) /? actin in serious Carcimoma was 0.75 ?0.22, in mucious carcinoma 1.03 ?0.28, in endometrioid carcinoma 0.57 ?0.11, there were significant differences among the three histological subtypes(P<0.05); Negative correlations were found between the MDR_(1) expression level (specially in high) and the antitumor activity of ADM and VCR in subrenal capsule assay. Conclusion:There are intrinsic MDR_(1) expression in all untreated ovarian carcinomas, and the MDR_(1) expression may lead the chemoresistance of MDR_(1) related drug. Therefore, MDR_(1) related drugs should combined with MDR_(1) reverse agents and MDR_(1) unrelated drugs in the overian carcinoma treatment at the very begining.
出处
《临床肿瘤学杂志》
CAS
2000年第4期237-239,共3页
Chinese Clinical Oncology
基金
本课题曾获青岛市科技进步二等奖
